Placebo to keytruda - Normal saline solution
Sponsors
Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC
Conditions
Cis-eligible Muscle-invasive bladder cancer.Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinoma
(LA cSCC)
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
Active, not recruitingCTIS2022-500395-57-00
Start: 2019-03-04Target: 267Updated: 2025-10-08
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
Active, not recruitingCTIS2022-501970-20-01
Start: 2019-06-07Target: 430Updated: 2025-10-16